12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Urocidin: Phase III discontinued

Endo discontinued the open-label, international Phase III EMBARC-RF trial of Urocidin, citing a lower-than-expected recruitment rate and discussions with FDA regarding the trial's design. The trial was comparing Urocidin vs....

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >